


## (R)-GSK-3685032

<b>Cat. No.:</b>	HY-139664A
<b>CAS No.:</b>	2170140-50-6
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>24</sub> N <sub>6</sub> OS
<b>Molecular Weight:</b>	420.53
<b>Target:</b>	DNA Methyltransferase
<b>Pathway:</b>	Epigenetics
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 60 mg/mL (142.68 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.3780 mL	11.8898 mL	23.7795 mL
	5 mM	0.4756 mL	2.3780 mL	4.7559 mL
	10 mM	0.2378 mL	1.1890 mL	2.3780 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(R)-GSK-3685032 is the R-enantiomer of GSK-3685032. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC<sub>50</sub> of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

DNMT1

### REFERENCES

[1]. Adams, Nicholas David, et al. Substituted pyridines as inhibitors of DNMT1 and their preparation. WO2017216727A1.

[2]. Pappalardi MB, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002-1017.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA